DE · QIA.DE · MEDICAL - DIAGNOSTICS & RESEARCH
Qiagen N.V. (QIA.DE) intrinsic value and stock valuation
$45.07as of 2026-11-21 · Mkt cap 6.37B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Qiagen N.V. DCF and intrinsic value
InvestorsCraft values QIA.DE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from QIA.DE’s statements →
Qiagen N.V. Graham Number
Graham Number: $28.90d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.09B | $1.98B | $1.97B | $2.14B | $2.25B |
| Operating income | $520.4M | $97.7M | $409.9M | $531.5M | $630.1M |
| Net income | $424.9M | $83.6M | $341.3M | $423.2M | $512.6M |
| EPSd | $2.04M | $382.6K | $1.57M | $1.95M | $2.34M |
| Operating cash flow | $654.4M | $673.6M | $459.5M | $715.3M | $639M |
| Capital expenditure | -$-201.06M | -$-167.17M | -$-162.8M | -$-149.34M | -$-206.53M |
| Free cash flow | $453.3M | $506.4M | $296.7M | $565.9M | $432.5M |
| Total assets | $6.3B | $5.69B | $6.12B | $6.29B | $6.15B |
| Total debt | $1.65B | $1.51B | $1.53B | $1.86B | $1.98B |
| Net debt | $815.5M | $849M | $864M | $1.13B | $1.06B |
| Total equity | $3.78B | $3.57B | $3.81B | $3.47B | $3.1B |
| Cash and short-term investments | $1.1B | $1.15B | $1.06B | $1.42B | $1.07B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.09B | $1.98B | $1.97B | $2.14B | $2.25B |
| Cost of revenue | $798.6M | $653.4M | $731.6M | $757M | $733.7M |
| Gross profit | $1.29B | $1.32B | $1.23B | $1.38B | $1.52B |
| Research and development expenses | $187.5M | $193.5M | $198.5M | $189.9M | $190M |
| Selling, general and administrative expenses | $583.7M | $564.4M | $579.2M | $604M | $584.5M |
| Other expenses | $0.00 | $469.2M | $46.1M | $59.3M | $113.4M |
| Operating expenses | $771.2M | $1.23B | $823.8M | $853.1M | $887.9M |
| Cost and expenses | $1.57B | $1.88B | $1.56B | $1.61B | $1.62B |
| Interest income | $64.3M | $68M | $79M | $32.8M | $9.55M |
| Interest expense | $33.3M | $43.8M | $53.4M | $58.4M | $54.5M |
| Depreciation and amortization | $193.8M | $203.3M | $205.3M | $208.4M | $214.9M |
| Ebitda | $717.3M | $702.1M | $688.6M | $779.4M | $895.2M |
| Operating income | $520.4M | $97.7M | $409.9M | $531.5M | $630.1M |
| Total other income/expenses, net | -$-30.05M | $23.4M | $19.9M | -$-18.86M | -$-4.25M |
| Income before tax | $490.3M | $121.2M | $429.8M | $512.6M | $625.8M |
| Income tax expense | $65.4M | $37.6M | $88.5M | $89.4M | $113.2M |
| Net income | $424.9M | $83.6M | $341.3M | $423.2M | $512.6M |
| Weighted average shares outstanding | $207.9M | $216.4M | $215.2M | $214.6M | $215M |
| Weighted average diluted shares outstanding | $207.9M | $218.5M | $217.5M | $217M | $218.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.1B | $1.15B | $1.06B | $1.42B | $1.07B |
| Net receivables | $402.6M | $459M | $515.6M | $333.5M | $469.7M |
| Inventory | $301.9M | $279.3M | $398.4M | $358M | $327.5M |
| Total current assets | $2B | $1.96B | $2.15B | $2.39B | $2.11B |
| Property, plant and equipment, net | $924M | $753.6M | $870.3M | $662.2M | $638.2M |
| Goodwill and intangible assets | $3.09B | $2.73B | $3B | $2.9B | $2.98B |
| Long-term investments | $0.00 | $19.3M | $23.7M | $23.6M | $0.00 |
| Total non-current assets | $4.3B | $3.73B | $3.97B | $3.89B | $4.04B |
| Total assets | $6.3B | $5.69B | $6.12B | $6.29B | $6.15B |
| Accounts payable | $72.7M | $83.3M | $84.2M | $98.7M | $101.2M |
| Short-term debt | $0.00 | $77.8M | $610.2M | $411.8M | $869.7M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $69M | $63.4M |
| Total current liabilities | $512.2M | $543.6M | $1.08B | $974.5M | $1.52B |
| Long-term debt | $1.65B | $1.43B | $1.1B | $1.58B | $1.24B |
| Deferred revenue, non-current | $0.00 | $18M | $15.6M | $15.2M | $11.3M |
| Total non-current liabilities | $2.01B | $1.58B | $1.23B | $1.85B | $1.53B |
| Capital lease obligations | $0.00 | $121M | $101.3M | $93.6M | $98.6M |
| Total liabilities | $2.52B | $2.12B | $2.31B | $2.82B | $3.05B |
| Common stock | $2.53M | $2.6M | $2.7M | $2.7M | $2.7M |
| Retained earnings | $2.75B | $2.45B | $2.46B | $2.16B | $1.79B |
| Accumulated other comprehensive income (loss) | -$-377.33M | -$-474.54M | -$-433.83M | -$-404.09M | -$-326.67M |
| Total equity | $3.78B | $3.57B | $3.81B | $3.47B | $3.1B |
| Total investments | $259.9M | $508.7M | $413.4M | $711.1M | $184.8M |
| Total debt | $1.65B | $1.51B | $1.53B | $1.86B | $1.98B |
| Net debt | $815.5M | $849M | $864M | $1.13B | $1.06B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $424.9M | $83.6M | $341.3M | $423.2M | $512.6M |
| Depreciation and amortization | $193.8M | $221.7M | $205.3M | $208.4M | $214.9M |
| Stock-based compensation | $0.00 | $43.6M | $47.1M | $49.5M | $38.4M |
| Change in working capital | -$-34.52M | $135.5M | -$-186.96M | -$-31.88M | -$-130.01M |
| Accounts receivable | -$-36.39M | $12.2M | -$-55.12M | $15.5M | -$-7.4M |
| Inventory | -$-850K | $87.8M | -$-44.79M | -$-61.95M | -$-81.8M |
| Accounts payable | -$-8.42M | $1.45M | -$-22.42M | -$-1.76M | -$-5.97M |
| Net cash provided by operating activities | $654.4M | $673.6M | $459.5M | $715.3M | $639M |
| Investments in property, plant and equipment | -$-207.14M | -$-167.17M | -$-149.71M | -$-149.34M | -$-206.53M |
| Acquisitions, net | -$-291.25M | $0.00 | -$-149.53M | -$-63.65M | -$-16.63M |
| Net cash used for investing activities | -$-305.3M | -$-249.23M | -$-87.66M | -$-726.76M | -$-202.43M |
| Common stock issued | $0.00 | $0.00 | $36.9M | $120K | $7.92M |
| Common stock repurchased | -$-280.11M | -$-326.26M | -$-17.68M | -$-25.36M | -$-99.99M |
| Dividends paid | -$-54.25M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-178.99M | -$-422.9M | -$-433.83M | -$-125.8M | -$-150.37M |
| Net change in cash | $86.2M | -$-4.53M | -$-62.59M | -$-149.85M | $282.5M |
| Cash at end of period | $839.1M | $663.6M | $668.1M | $730.7M | $880.5M |
| Operating cash flow | $654.4M | $673.6M | $459.5M | $715.3M | $639M |
| Capital expenditure | -$-201.06M | -$-167.17M | -$-162.8M | -$-149.34M | -$-206.53M |
| Free cash flow | $453.3M | $506.4M | $296.7M | $565.9M | $432.5M |
Line items
Line items
Line items
About Qiagen N.V.
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
- CEO
- Thierry L. Bernard
- Employees
- 5.7K
- Beta
- 0.64
Included in
Explore
Frequently asked questions
What is the intrinsic value of Qiagen N.V. (QIA.DE)?
InvestorsCraft does not currently publish an intrinsic value for QIA.DE. How the IC value is calculated.
Is QIA.DE undervalued?
InvestorsCraft does not publish an undervaluation signal for QIA.DE at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.